Lv3
210 积分 2024-10-28 加入
Diagnosis and Treatment of Myelodysplastic Syndromes
5天前
已完结
Clinical outcomes of combination treatment with FMS‐like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia
6天前
已完结
Influence of IDH on FLT3-ITD status in newly diagnosed AML
6天前
已完结
Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome
14天前
已完结
Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022
15天前
已完结
Single-cell mutation analysis of clonal evolution in myeloid malignancies
18天前
已完结
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy
1个月前
已完结
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
1个月前
已完结
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1 -Mutated Acute Myeloid Leukemia
1个月前
已完结
皖公网安备34019202002308
